PDS Biotechnology Highlights Promising Phase 2 Prostate Cancer Data

PDS Biotechnology ( (PDSB) ) has issued an announcement.

On January 28, 2026, PDS Biotechnology announced that the National Cancer Institute presented preliminary Phase 2 results for its investigational IL-12 tumor-targeted immunocytokine PDS01ADC at an American Association for Cancer Research conference on prostate cancer held in Boston on January 20-22, 2026. The NCI-led study evaluated PDS01ADC in combination with docetaxel in patients with metastatic castration-resistant prostate cancer who had largely exhausted second-line androgen-targeted therapies, reporting a median progression-free survival of 9.6 months and a median PSA decline of 40%, with six of 16 patients achieving PSA reductions greater than 50%. The data, highlighting the agent’s tumor-targeted IL-12 mechanism via binding to necrotic DNA, bolster PDS Biotech’s immuno-oncology pipeline by suggesting the potential to enhance existing therapies in difficult-to-treat solid tumors, an important signal for the company’s strategic positioning in late-stage cancer immunotherapy development.

The most recent analyst rating on (PDSB) stock is a Hold with a $0.93 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, and a materially reduced equity base), which elevates financing risk. Partially offsetting this are constructive clinical/regulatory updates from the earnings call and a neutral-to-slightly positive near-term technical picture, while valuation remains constrained by negative earnings and no dividend support.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, with a pivotal clinical trial underway for its lead program in advanced HPV16-positive head and neck squamous cell cancers. Its lead investigational targeted immunotherapy, PDS0101 (Versamune® HPV), is being developed in combination with a standard-of-care immune checkpoint inhibitor and in a triple combination that includes PDS01ADC, an IL-12 fused antibody-drug conjugate, alongside a checkpoint inhibitor.

Average Trading Volume: 883,596

Technical Sentiment Signal: Strong Sell

Current Market Cap: $49.37M

For detailed information about PDSB stock, go to TipRanks’ Stock Analysis page.